Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tacey White

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Reproductive Toxicology (Elmsford, N.Y.)|August 28, 2016
Comment on Sweeting and Wells (2015)Tacey White, Amy Williams, John M DeSesso
Nucleic Acid Therapeutics|August 20, 2014
Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeuticsJoy Cavagnaro, Cindy Berman, Doug Kornbrust, et al.
Regulatory Toxicology and Pharmacology : RTP|January 1, 2025
The dual endothelin A and angiotensin II type 1 receptor antagonist sparsentan (FILSPARI®) exhibits a safe nonclinical male fertility toxicity profilePatricia W Bedard, Francesca Pretto, Sima Patel, et al.
Birth Defects Research|February 12, 2024
HESI workshop summary: Interpretation of developmental and reproductive toxicity endpoints and the impact on data interpretation of adverse eventsM L Green, A Kluever, Connie Chen, et al.
Birth Defects Research|June 5, 2026
Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical TrialsDinesh Stanislaus, Christopher J Bowman, Kimberly C Brannen, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Reproductive Toxicology (Elmsford, N.Y.)|August 28, 2016
Comment on Sweeting and Wells (2015)Tacey White, Amy Williams, John M DeSesso
Nucleic Acid Therapeutics|August 20, 2014
Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeuticsJoy Cavagnaro, Cindy Berman, Doug Kornbrust, et al.
Regulatory Toxicology and Pharmacology : RTP|January 1, 2025
The dual endothelin A and angiotensin II type 1 receptor antagonist sparsentan (FILSPARI®) exhibits a safe nonclinical male fertility toxicity profilePatricia W Bedard, Francesca Pretto, Sima Patel, et al.
Birth Defects Research|February 12, 2024
HESI workshop summary: Interpretation of developmental and reproductive toxicity endpoints and the impact on data interpretation of adverse eventsM L Green, A Kluever, Connie Chen, et al.
Birth Defects Research|June 5, 2026
Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical TrialsDinesh Stanislaus, Christopher J Bowman, Kimberly C Brannen, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Pageof 1